Acta Scientific Neurology (ISSN: 2582-1121)

Volume 5 Issue 6 June 2022

Review Article

Prevention of Induced L-Dopa Dyskinesias Through Closed Loop Adaptive Deep Brain Stimulation in Parkinson`s: Stimulations with DBS Stimulator

Venkateshwarla Rama Raju[1]* and Dabbeta Anji Reddy[2]

[1]PhD, Professor, Department of Computer Science and Engineering

[2]PhD, Professor, Director Nigama Engineering College

Sambaipally, Peddapally Karimanagar, Telangana, India

***Corresponding Author:** Venkateshwarla Rama Raju, PhD Department of Computer Science & Engineering CMR College of Engineering & Technology (UGC Autonomous) [Jawaharlal Nehru technological University Hyderabad - JNTUH] CMR Institute of Medical Sciences (CMR-IMS) Kandlakoya, Medchal Rd., Hyderabad, Telangana TS 501 401, India. email: drvenkateshwararrr@gmail.com

DOI: 10.31080/ASNE.2022.05.0511

Received: April 19, 2022

Published: May 27, 2022

Abstract

This study presents the prevention of dyskinesias called side-effects occurred due to the induced levodopa (IL-Dopa, a metabolic precursor to the dopamine chemical messengers which are cell receptors) by applying the minimally invasive surgical procedure called deep brain stimulation - a surgery done for the Parkinson`s disease patients such that the dyskinesias such as cognitive issues like memory, cognitive impairment CI, cognitive dementia CD, slurred speech, hallucinations, followed by the axial symptoms of the entire body shaking like breezing, etc.) are wiped out.

Keywords: L-Dopa; Dyskinesias; Closed Loop; Deep Brain Stimulation; Parkinson`s

Introduction

The potential-benefits of adaptive closed loop deep brain stimulation (ACL-DBS) approaches [1] contrasted to, or equated with the constant, conventional, and continuous steady-open-loop DBS (COL-DBS) parameters were previously demonstrated through appropriate validation with scientific-objective-evidence from as of diverse experimental-research-investigators [2-4]. The Adaptive-closed-loop DBS gives better feature-manifestations that are signs and symptoms prevention in Parkinson's disease (PD) subjects who are patients with adjusting the induced stimulus electrical DBS parameters to the subjects, i.e., patient's clinical/and or diagnostic-state estimated through the analysis of subthalamic nucleus (STN) neural or neuronal-oscillations (i.e., local-field-potentials) in the $\beta - band$ beta-band frequency, from 13Hertz to 30Hertz) [5].

For the reason that ACL-DBS hospital management was certainly-systematically not measured throughout lengthy and protracted DBS stimulus phases in further ecologic-conditions, we verified uni-lateral ACL-DBS delivered for approximately circa ~2 and ½ hours, with specific-focus on the parallel managementof L-Dopa-therapeutic-treatment, in the patients those who are spontaneously heart-rendingly moving with parkinsonism disease [6-15].

Management

We therefore arbitrarily administered with ACL-DBS as well as COL-DBS through and through an external habiliment-vesture, i.e., wearable-model-prototype [6,7] in ten Parkinson`s disease subjects(patients) together with in conjunction with deep brain stimulation stimulus microelectrode implant/embedding

in two distinct experimental-investigational-phases or/sessions taking-place the fifth and the sixth day following the deep brain stimulation operational surgery (Figure 1 A) [16-20].

Figure 1: Experimental design of every exploratory phase.

- Experimental effects were assessed estimated and then validated by employing the United Kingdom Brain Data criteria and followed by the motoric chunk of the Unified Parkinson`s Disease Rating Scale stage III following H and Y score (i.e.,UPDRS, stage-III) and the Unified Parkinson Disease Dyskinesia Rating Scale (UPDDysRS stages-III and IV) for the duration of the concurrently simultaneous parallel management processing of adaptive closed loop - deep brain stimulation or constant and conventional open loop deep brain stimulation (ACL-DBS or COL-DBS) and levodopa (L-Dopa).
- The Unified Parkinson`s Disease Rating Scale stage III following H and Y score (i.e., UPDRS, stage-III) as well the Unified Parkinson Disease Dyskinesia Rating Scale (UPDDysRS stages-III and IV) for the duration of the concurrently simultaneous parallel management processing of adaptive closed loop - deep brain stimulation or constant and conventional open loop deep brain stimulation (ACL-DBS or COL-DBS) and levodopa (L-Dopa), normalized for the optimal-score amongst ACL-DBS and COL-DBS.
- Total electrical-energy delivered (TEED) per unit-of-time (l-W) for ACL-DBS (the white-color) and COL-DBS (the gray-color). Error(erratic-bras) bars exemplify or signify the standard-error (SE). The termed designations “MED” represents the medication and “STIM” represents the stimulation/or stimuli or stimulus by the deep brain stimulation (termed DBS).

Every experimental phase lasted for two (2) hours, during which the Parkinson subject, i.e., the patient, following a electrical-baseline, i.e., zero-line evaluation (“DBS-OFF” and “MED OFF”, followed by “STIM-OFF”/”MED-OFF”), received both L-Dopa(levodopa) as well as induced stimulus (ACL-DBS or COL-DBS), therefore, consequently letting one to examine the contact amongst electrical-stimulation by observing with the stimulus intensity (for the amplitudes levels) and pharmaco-logical-stimulations (“DBS-ON” and “MED-ON”, STIM-ON/MED-ON) [21-24]. The subject, i.e., the Parkinson diseased patient was blind to the class of stimulation’s with the deep brain stimulation (DBS) received in the course of the throughout the sessional-phase as well as for the entire-duration of the phase-period [25].

Results and Discussion

The clinical-diagnosis-effects were blindly estimated in the course of the UPDRS-stage-III (motoric-part) and the Unified Parkinson`s disease Dyskinesia Rating Scale (UPDDysRS). In accordance with the gold-standard levodopa, the clinical-evaluation was accomplished through a blinded video-rater (the motoric-rigidity-symptom -scores were omitted or barred from the inferences-deduced through rigorous-analytic-part, i.e., analysis-part) [26].

The overall electrical-current i.e., voltage or/electrical-energy-delivered (TEED) was employed for energy-efficiency-evaluation as well as dysarthria’s like adverse-effects or adverse-events were gathered for safety and security-evaluation and efficacy [27-32].

The diagnostic-clinical-scores were significantly not distinct amongst the two experimental-investigation-phases/sessions at electrical-baseline, i.e., zero-line (DBS-OFF/ MED-OFF, UPDRS-stage-III scale and Horn and Y score, ACL-DBS versus COL-DBS: 38.0 6 16.9 versus 37.6 6 16.4; F1,95 0.2, P >0.05, not significant) [28].

Once the Parkinson`s diseased subject, the patient was in the consequence of together with L-Dopa(Levodopa) as well as DBS (DBS-ON/MED-ON), we identified and examined an analogous development or enhancement on universal motoric-symptoms that are signs and feature-manifestations irrespective to the kind of DBS-devices (UK brain bank criterion, UPDRS -stage-III percent alteration from electrical-baseline, i.e., standard zero-line, ACL-DBS versus COL-DBS: 247.2% 6 11.% versus 241.1% 6 18%; F1,9 5 0.7, P > 0.05;Figure.1.B.). Conversely, in this condition, ACL-DBS was more effective on dyskinesias than COL-DBS (UPDDysRS score, ACL-DBS versus COL-DBS: 11.7 6 68 versus 15.0 6 9.4; F1,9 5 6.1, P5.02; Figure1C). These findings were achieved in conjunction with a standard and normal, i.e.,average-power redeeming or economy reduction of 73.9% 6 24% in ACL-DBS contrasted with COL-DBS (the average-mean TEED ACL-DBS versus COL-DBS: 44.6 6 47.9 l-W versus 158.7 6 69.7 l-W; F1,8 5 30.4, P5.0005).

During the whole experimentation, there were no significant dysarthria's, i.e., adverse-effects or/events particularly connected with the stimulus deep brain stimulator. The findings provide for the notion that ACL-DBS, being efficacious and efficient, and effective, and safe and secure, while managed concurrently or synchronously to L-Dopa (the metabolic precursor to dopamine chemical messengers) might assist the neuroscientist-clinicians limit the sternness of dyskinesias what we call side-effects induced through the passing/transient summation of stimulations by the deep brain stimulator 9D B S) i.e., by the deep brain stimulator (DBS) but not 9DBS.

Conclusion

Nevertheless, the critical experimental-setting, considered through a microlesion (microlesioned or micro-lesional)-effect as well as through the occurrence and existence of edemas, is a foremost prime restraint for the generalizability of our findings which needs to be deep-rooted inveterate (or/confirmed) through the other investigational exploratory studies (through experimental) conducted in a supplementary long-lasting state, probably through the implantable devices.

Bibliography

1. A Priori., *et al*. "Adaptive deep brain stimulation (aDBS) controlled by local field potential oscillations". *Journal of Experimental Neurology* 245 (2013): 77-86.
2. S Little., *et al*. "Adaptive deep brain stimulation in advanced Parkinson disease". *Annals of Neurology* 74 (2013): 449-457.
3. S Little., *et al*. "Bilateral adaptive deep brain stimulation is effective in Parkinson's disease". *Journal of Neurology and Neurosurgery andPsychiatry* 87 (2016): 717-721.
4. M Rosa., *et al*. "Adaptive deep brain stimulation in a freely moving Parkinsonian patient". *Movement Disorders* 30 (2015): 1003-1005.
5. M Arlotti., *et al*. "The adaptive deep brain stimulation challenge". *Parkinsonism Related Disorders* 28 (2016): 12-17.
6. M Arlotti., *et al*. "An external portable device for adaptive deep brain stimulation (aDBS) clinical research in advanced Parkinson's disease". *Medical Engineering and Physics* 38 (2016): 498-505.
7. R Jankovic J. "Parkinson's disease: clinical features and diagnosis". *Journal of Neurology, Neurosurgery and Psychiatry* 79 (2008): 368-376.
8. Fahn S and Elton RL. "The Unified Parkinsons Disease Rating Scale". Recent developments in Parkinsons disease. Florham Park, N.J: Macmillan Healthcare Information (1987): 153-163.
9. Antoniades CA and Barker RA. "The search for biomarkers in Parkinsons disease: a critical review". *Expert Review* 8.12 (2008): 1841-1852.
10. Morgan JC., *et al*. "Biomarkers in Parkinsons disease". *Current Neurology and Neuroscience Reports* 10 (2010): 423-430.
11. Evelyn Strauss, LASKER FOUNDATION. Lasker~DeBakey Clinical Medical Research Award to Alim Louis Benabid and Mahlon DeLong (2014): 1-4.
12. Amirnovin R., *et al*. "Experience with microelectrode guided subthalamic nucleus deep brain stimulation". *Neurosurgery* 58.1 (2006): ONS96-102.
13. Kyriaki Kostoglou. "Classification and Prediction of Clinical Improvement in Deep Brain Stimulation from Intraoperative Microelectrode Recording, IEEE Trans". *BME* 64.5 (2017): 1123-1130.

14. Sang Jin Kim., *et al*. "Effects of Subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease". *Neurology* 85 (2015): 425-432.

15. Bour LJ., *et al*. "Long term experience with intraoperative microrecording during DBS neurosurgery in STN and Gpi". *Acta Neurochirurgica*152.12 (2010): 2069-2077.

16. Zuan He. "Neural Signal processing of microelectrode recordings for deep brain stimulation, Chalmers University of Technology (2009).

17. AL Benabid. "Deep brain stimulation for Parkinson's disease". *Current Opinion in Neurobiology* 13.6 (2003): 696-706.

18. AL Benabid., *et al*. "Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease". *Stereotactic and Functional Neurosurgery* 62.1-4 (1994): 76-84.

19. A Moran., *et al*. "Subthalamic nucleus functional organization revealed by Parkinsonian neuronal oscillations and synchrony". *Brain* 131.12 (2008): 3395-3409.

20. GL Defer. "Core assessment program for surgical intervention therapies in Parkinson's disease". *Movement Disorder* 14.4 (1999): 572-584.

21. Andrade-Souza YM., *et al*. "Comparison of three methods of targeting the subthalamic nucleus for chronic stimulation in Parkinson's disease". *Neurosurgery* 62.2 (2008): 875-883.

22. Larry Squire., *et al*. "Fundamental Neuroscience, 4th Editon". AP Academic Press (2012).

23. McClelland S. "A cost analysis of intraoperative microelectrode recording during subthalamic stimulation for Parkinson's disease". *Movement Disorder* (2011).

24. William H Press., *et al*. "Numerical Recipes in C++, Cambridge University Press" (2002).

25. Andrzej Dobrowolski., *et al*. "Spectral Analysis of Motor Unit Action Potentials". *IEEE Transactions on Biomedical Engineering* 54.12 (2007): 2300-2302.

26. Sabato Santaniello., *et al*. "Therapeutic mechanisms of high-frequency stimulation in Parkinson`s disease and neural restoration via loop-based reinforcement". *Proceedings of the National Academy of sciences* (2015): 1-10.

27. Sridevi V Sarma., *et al*. "Using point process models to compare neural spiking activity in the subthalamic nucleus of Parkinson`s patients and a healthy primate". *IEEE Transactions on Biomedical Engineering* 57.6 (2010): 1297-1305.

28. Hans S., *et al*. "Electrical stimulation inhibits cytosine arabinoside-induce neuronal death by preventing apoptosis in dorsal root ganglion neurons". *NeuroReport* (2016).

29. V Rama Raju., *et al*. "Latent Variate Factorial Principal Component Analysis of Microelectrode Recording of Subthalamic Nuclei Neural Signals with Deep Brain Stimulator in Parkinson Diseaseet.al. Springer Briefs in Forensic and Medical Bioinformatics". *Soft Computing and Medical Bioinformatics* (2018).

30. V Rama Raju. "Principal component latent variate factorial analysis of MER signals of STN-DBS in Parkinson`s disease (Electrode Implantation)". Springer Nature 68.3 (2018).

31. V Rama Raju., *et al*. "The Role of Microelectrode Recording (MER) in STN DBS Electrode Implantation". IFMBE Proceedings, Springer, 51, World Congress on Medical Physics and Biomedical Engineering, June 7-12, 2015, Toronto, Canada (2018): 1204-1208.